**1. Phylogeny:**  
G protein‐coupled receptor kinase 4 (GRK4) is a member of the GRK family of serine/threonine kinases that evolved to mediate the phosphorylation of activated G protein‐coupled receptors. Within the kinome, GRK4 is assigned to the GRK4 subfamily together with GRK5 and GRK6, which is phylogenetically distinct from the GRK1 (rhodopsin kinase/GRK7) and GRK2 (β‐adrenergic receptor kinases) subfamilies (allen2015structureandfunction pages 1-2, gurevich2012gproteincoupledreceptor pages 1-2). Orthologs of GRK4 are conserved among vertebrate species as part of an evolutionary expansion that involved gene duplication events, with its kinase domain and regulatory regions maintained within the conserved AGC kinase fold class. GRK4 is predominantly expressed in restricted tissues such as the testis, kidney proximal tubule cells, and the cerebellum, which reflects both its specialized physiological roles and its evolutionary divergence from more ubiquitously expressed GRKs (allen2015structureandfunction pages 1-2, mushegian2012theoriginand pages 10-11, packiriswamy2015gproteincoupledreceptorkinases pages 2-4).

**2. Reaction Catalyzed:**  
GRK4 catalyzes the transfer of the γ-phosphate from ATP to specific serine or threonine residues on activated G protein‐coupled receptors. In this reaction, ATP is converted into ADP while the receptor becomes phosphorylated at key serine/threonine sites, thereby initiating receptor desensitization and subsequent arrestin recruitment. The overall chemical reaction is represented as follows: ATP + [protein]-(L-serine or L-threonine) → ADP + [protein]-(L-serine/threonine)-phosphate + H⁺ (allen2015structureandfunction pages 2-3, jose2010dopamineandg pages 7-8).

**3. Cofactor Requirements:**  
The catalytic activity of GRK4 is dependent on the presence of ATP and requires divalent metal ions, with Mg²⁺ serving as a critical cofactor. This requirement for Mg²⁺, which is common to serine/threonine kinases, facilitates the proper positioning of ATP within the catalytic site and promotes efficient phosphoryl transfer (allen2015structureandfunction pages 2-3, gurevich2012gproteincoupledreceptor pages 1-2).

**4. Substrate Specificity:**  
GRK4 exhibits a high degree of substrate specificity for agonist-activated G protein‐coupled receptors. Notably, the GRK4-alpha isoform is capable of phosphorylating rhodopsin, whereas the other three isoforms do not phosphorylate rhodopsin and lack interaction with calmodulin. In addition, both GRK4-alpha and GRK4-gamma have been shown to phosphorylate the dopamine receptor subtype D3 (DRD3). GRK4 also phosphorylates the beta-2 adrenergic receptor (ADRB2), which is consistent with the general mechanism by which GRKs catalyze the phosphorylation of activated GPCRs on serine/threonine clusters. Although a precise consensus substrate motif for GRK4 has not been delineated in the available texts, its specificity aligns with that observed for other GRK family members that target serine/threonine residues typically adjacent to clusters of basic amino acids (allen2015structureandfunction pages 1-2, jose2010dopamineandg pages 7-8, gurevich2012gproteincoupledreceptor pages 13-15).

**5. Structure:**  
GRK4 exhibits a canonical domain organization characteristic of the GRK family. It possesses a short, unique N-terminal region that is implicated in receptor binding and allosteric activation. This is followed by an RGS (regulator of G protein signaling) homology domain, which contributes to the overall regulatory interactions and possibly aids in maintaining the kinase’s low basal activity. Centrally, GRK4 contains a highly conserved serine/threonine kinase domain, which adopts the typical AGC kinase bilobal fold and contains key catalytic motifs such as the DFG (or DLG) motif at the start of the activation loop. High-resolution structural studies, including crystal structures of the hypertension-associated GRK4 A486V variant, demonstrate that the N-terminal region assumes an α-helical conformation that is required for full catalytic activity and efficient receptor docking (allen2015structureandfunction pages 6-7, gurevich2012gproteincoupledreceptor pages 6-8). Alternative splicing produces four GRK4 isoforms—namely GRK4-alpha, -beta, -gamma, and -delta—which differ primarily by the presence or absence of specific exons that encode portions of the RGS homology domain and the C-terminal region (allen2015structureandfunction pages 4-5). The divergent C-terminal region contains determinants for membrane association, including palmitoylation sites and positively charged lipid-binding motifs, which facilitate GRK4’s localization to the plasma membrane (gurevich2012gproteincoupledreceptor pages 1-2, packiriswamy2015gproteincoupledreceptorkinases pages 2-4). Key regulatory features include an ordered activation loop harboring autophosphorylation sites such as Ser485, essential for achieving full kinase activity (allen2015structureandfunction pages 9-10).

**6. Regulation:**  
The regulation of GRK4 involves a combination of post-translational modifications and interactions with regulatory proteins. Autophosphorylation of the kinase C-tail, particularly at serine residues such as Ser485, is critical for full activation of its catalytic function (allen2015structureandfunction pages 1-2, allen2015structureandfunction pages 9-10). In the case of the GRK4-alpha isoform, its kinase activity is specifically inhibited by calmodulin binding, a property that is not shared by the other GRK4 isoforms, indicating isoform-specific regulatory mechanisms (jose2010dopamineandg pages 7-8, allen2015structureandfunction pages 1-2). Alternative splicing further modulates GRK4 activity by generating isoforms that differ in regulatory interactions and receptor substrate specificity (allen2015structureandfunction pages 4-5, gurevich2012gproteincoupledreceptor pages 2-4). Additionally, membrane recruitment and efficient receptor phosphorylation depend on lipid interactions; GRK4 contains C-terminal palmitoylation sites and a basic interface that interacts with phosphatidylinositol 4,5-bisphosphate (PIP2), thereby positioning the enzyme at the cytoplasmic face of the plasma membrane where its GPCR substrates reside (sulon2021targetinggprotein–coupled pages 14-16, gurevich2012gproteincoupledreceptor pages 6-8, packiriswamy2015gproteincoupledreceptorkinases pages 2-4).

**7. Function:**  
GRK4 functions primarily to phosphorylate activated G protein‐coupled receptors, facilitating receptor desensitization through enhanced binding of β-arrestins and subsequent receptor internalization. In its role as a GPCR kinase, GRK4 contributes to signal termination and receptor recycling, which are essential for maintaining cellular responsiveness. The GRK4-alpha isoform uniquely phosphorylates rhodopsin, implicating it in photoreceptor signaling, although its expression in the retina is limited in comparison to GRK1 and GRK7. In contrast, GRK4-alpha and GRK4-gamma phosphorylate the dopamine receptor DRD3, and GRK4 also phosphorylates ADRB2, thereby influencing dopaminergic and adrenergic signaling pathways. GRK4 is highly expressed in the kidney’s proximal tubules, where it plays a pivotal role in regulating renal dopamine receptor function and is linked to the modulation of sodium excretion and blood pressure regulation. Genetic variants of GRK4, including polymorphisms such as R65L, A142V, and A486V, have been associated with essential hypertension and salt sensitivity, underscoring its physiological importance in cardiovascular regulation (allen2015structureandfunction pages 1-2, jose2010dopamineandg pages 15-16, rayner2015theimportanceof pages 8-9, yang2015gproteincoupledreceptor pages 1-2).

**8. Other Comments:**  
While the development of specific inhibitors for GRK4 remains less advanced compared to other GRK family members, its distinct isoform-specific properties, such as the calmodulin-dependent inhibition observed in GRK4-alpha, highlight its potential as a therapeutic target in hypertension and cardiovascular diseases. The association of GRK4 gene variants with altered receptor phosphorylation patterns further supports its involvement in the dysregulation of GPCR signaling pathways in pathological conditions. Moreover, GRK4’s role in phosphorylating dopamine receptors and ADRB2 emphasizes its significance in renal and cardiac function. The differential effects of alternative splicing on GRK4’s regulatory and catalytic activities call for additional research that may uncover novel therapeutic approaches targeting its unique regulatory mechanisms (gurevich2012gproteincoupledreceptor pages 57-59, sulon2021targetinggprotein–coupled pages 7-9).

**9. References:**  
1. allen2015structureandfunction pages 1-2  
2. allen2015structureandfunction pages 2-3  
3. allen2015structureandfunction pages 4-5  
4. allen2015structureandfunction pages 6-7  
5. allen2015structureandfunction pages 9-10  
6. allen2015structureandfunction pages 14-15  
7. gurevich2012gproteincoupledreceptor pages 1-2  
8. gurevich2012gproteincoupledreceptor pages 2-4  
9. gurevich2012gproteincoupledreceptor pages 6-8  
10. gurevich2012gproteincoupledreceptor pages 13-15  
11. gurevich2012gproteincoupledreceptor pages 25-27  
12. jose2010dopamineandg pages 7-8  
13. jose2010dopamineandg pages 15-16  
14. rayner2015theimportanceof pages 8-9  
15. mushegian2012theoriginand pages 10-11  
16. packiriswamy2015gproteincoupledreceptorkinases pages 2-4  
17. sulon2021targetinggprotein–coupled pages 14-16  
18. yang2015gproteincoupledreceptor pages 1-2  
19. sulon2021targetinggprotein–coupled pages 7-9  
20. sulon2021targetinggprotein–coupled pages 3-4  
21. gurevich2012gproteincoupledreceptor pages 57-59

References

1. (allen2015structureandfunction pages 1-2): S. Allen, G. Parthasarathy, P. Darke, R. Diehl, Rachael E Ford, D. Hall, Scott A. Johnson, J. Reid, K. Rickert, J. Shipman, S. Soisson, P. Zuck, S. Munshi, and K. Lumb. Structure and function of the hypertension variant a486v of g protein-coupled receptor kinase 4\*. The Journal of Biological Chemistry, 290:20360-20373, Jul 2015. URL: https://doi.org/10.1074/jbc.m115.648907, doi:10.1074/jbc.m115.648907. This article has 25 citations.
2. (allen2015structureandfunction pages 2-3): S. Allen, G. Parthasarathy, P. Darke, R. Diehl, Rachael E Ford, D. Hall, Scott A. Johnson, J. Reid, K. Rickert, J. Shipman, S. Soisson, P. Zuck, S. Munshi, and K. Lumb. Structure and function of the hypertension variant a486v of g protein-coupled receptor kinase 4\*. The Journal of Biological Chemistry, 290:20360-20373, Jul 2015. URL: https://doi.org/10.1074/jbc.m115.648907, doi:10.1074/jbc.m115.648907. This article has 25 citations.
3. (jose2010dopamineandg pages 7-8): Pedro A. Jose, Patricio Soares-da-Silva, Gilbert M. Eisner, and Robin A. Felder. Dopamine and g protein-coupled receptor kinase 4 in the kidney: role in blood pressure regulation. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1802:1259-1267, Dec 2010. URL: https://doi.org/10.1016/j.bbadis.2010.02.004, doi:10.1016/j.bbadis.2010.02.004. This article has 138 citations.
4. (allen2015structureandfunction pages 14-15): S. Allen, G. Parthasarathy, P. Darke, R. Diehl, Rachael E Ford, D. Hall, Scott A. Johnson, J. Reid, K. Rickert, J. Shipman, S. Soisson, P. Zuck, S. Munshi, and K. Lumb. Structure and function of the hypertension variant a486v of g protein-coupled receptor kinase 4\*. The Journal of Biological Chemistry, 290:20360-20373, Jul 2015. URL: https://doi.org/10.1074/jbc.m115.648907, doi:10.1074/jbc.m115.648907. This article has 25 citations.
5. (allen2015structureandfunction pages 4-5): S. Allen, G. Parthasarathy, P. Darke, R. Diehl, Rachael E Ford, D. Hall, Scott A. Johnson, J. Reid, K. Rickert, J. Shipman, S. Soisson, P. Zuck, S. Munshi, and K. Lumb. Structure and function of the hypertension variant a486v of g protein-coupled receptor kinase 4\*. The Journal of Biological Chemistry, 290:20360-20373, Jul 2015. URL: https://doi.org/10.1074/jbc.m115.648907, doi:10.1074/jbc.m115.648907. This article has 25 citations.
6. (allen2015structureandfunction pages 6-7): S. Allen, G. Parthasarathy, P. Darke, R. Diehl, Rachael E Ford, D. Hall, Scott A. Johnson, J. Reid, K. Rickert, J. Shipman, S. Soisson, P. Zuck, S. Munshi, and K. Lumb. Structure and function of the hypertension variant a486v of g protein-coupled receptor kinase 4\*. The Journal of Biological Chemistry, 290:20360-20373, Jul 2015. URL: https://doi.org/10.1074/jbc.m115.648907, doi:10.1074/jbc.m115.648907. This article has 25 citations.
7. (allen2015structureandfunction pages 9-10): S. Allen, G. Parthasarathy, P. Darke, R. Diehl, Rachael E Ford, D. Hall, Scott A. Johnson, J. Reid, K. Rickert, J. Shipman, S. Soisson, P. Zuck, S. Munshi, and K. Lumb. Structure and function of the hypertension variant a486v of g protein-coupled receptor kinase 4\*. The Journal of Biological Chemistry, 290:20360-20373, Jul 2015. URL: https://doi.org/10.1074/jbc.m115.648907, doi:10.1074/jbc.m115.648907. This article has 25 citations.
8. (gurevich2012gproteincoupledreceptor pages 1-2): Eugenia V. Gurevich, John J.G. Tesmer, Arcady Mushegian, and Vsevolod V. Gurevich. G protein-coupled receptor kinases: more than just kinases and not only for gpcrs. Pharmacology & Therapeutics, 133:40-69, Jan 2012. URL: https://doi.org/10.1016/j.pharmthera.2011.08.001, doi:10.1016/j.pharmthera.2011.08.001. This article has 544 citations.
9. (gurevich2012gproteincoupledreceptor pages 2-4): Eugenia V. Gurevich, John J.G. Tesmer, Arcady Mushegian, and Vsevolod V. Gurevich. G protein-coupled receptor kinases: more than just kinases and not only for gpcrs. Pharmacology & Therapeutics, 133:40-69, Jan 2012. URL: https://doi.org/10.1016/j.pharmthera.2011.08.001, doi:10.1016/j.pharmthera.2011.08.001. This article has 544 citations.
10. (gurevich2012gproteincoupledreceptor pages 57-59): Eugenia V. Gurevich, John J.G. Tesmer, Arcady Mushegian, and Vsevolod V. Gurevich. G protein-coupled receptor kinases: more than just kinases and not only for gpcrs. Pharmacology & Therapeutics, 133:40-69, Jan 2012. URL: https://doi.org/10.1016/j.pharmthera.2011.08.001, doi:10.1016/j.pharmthera.2011.08.001. This article has 544 citations.
11. (jose2010dopamineandg pages 15-16): Pedro A. Jose, Patricio Soares-da-Silva, Gilbert M. Eisner, and Robin A. Felder. Dopamine and g protein-coupled receptor kinase 4 in the kidney: role in blood pressure regulation. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1802:1259-1267, Dec 2010. URL: https://doi.org/10.1016/j.bbadis.2010.02.004, doi:10.1016/j.bbadis.2010.02.004. This article has 138 citations.
12. (mushegian2012theoriginand pages 10-11): Arcady Mushegian, Vsevolod V. Gurevich, and Eugenia V. Gurevich. The origin and evolution of g protein-coupled receptor kinases. PLoS ONE, 7:e33806, Mar 2012. URL: https://doi.org/10.1371/journal.pone.0033806, doi:10.1371/journal.pone.0033806. This article has 94 citations and is from a peer-reviewed journal.
13. (packiriswamy2015gproteincoupledreceptorkinases pages 2-4): N Packiriswamy and N Parameswaran. G-protein-coupled receptor kinases in inflammation and disease. Genes & Immunity, 16:367-377, Sep 2015. URL: https://doi.org/10.1038/gene.2015.26, doi:10.1038/gene.2015.26. This article has 59 citations.
14. (yang2015gproteincoupledreceptor pages 1-2): Jian Yang, Van Anthony M. Villar, John E. Jones, Pedro A. Jose, and Chunyu Zeng. G protein-coupled receptor kinase 4. Hypertension, 65:1148-1155, Jun 2015. URL: https://doi.org/10.1161/hypertensionaha.115.05189, doi:10.1161/hypertensionaha.115.05189. This article has 43 citations and is from a domain leading peer-reviewed journal.
15. (gurevich2012gproteincoupledreceptor pages 13-15): Eugenia V. Gurevich, John J.G. Tesmer, Arcady Mushegian, and Vsevolod V. Gurevich. G protein-coupled receptor kinases: more than just kinases and not only for gpcrs. Pharmacology & Therapeutics, 133:40-69, Jan 2012. URL: https://doi.org/10.1016/j.pharmthera.2011.08.001, doi:10.1016/j.pharmthera.2011.08.001. This article has 544 citations.
16. (rayner2015theimportanceof pages 8-9): B. Rayner and Rajkumar Ramesar. The importance of g protein-coupled receptor kinase 4 (grk4) in pathogenesis of salt sensitivity, salt sensitive hypertension and response to antihypertensive treatment. International Journal of Molecular Sciences, 16:5741-5749, Mar 2015. URL: https://doi.org/10.3390/ijms16035741, doi:10.3390/ijms16035741. This article has 38 citations and is from a peer-reviewed journal.
17. (sulon2021targetinggprotein–coupled pages 14-16): Sarah M. Sulon and Jeffrey L. Benovic. Targeting g protein–coupled receptor kinases to g protein–coupled receptors. Current Opinion in Endocrine and Metabolic Research, 16:56-65, Feb 2021. URL: https://doi.org/10.1016/j.coemr.2020.09.002, doi:10.1016/j.coemr.2020.09.002. This article has 29 citations and is from a peer-reviewed journal.
18. (sulon2021targetinggprotein–coupled pages 3-4): Sarah M. Sulon and Jeffrey L. Benovic. Targeting g protein–coupled receptor kinases to g protein–coupled receptors. Current Opinion in Endocrine and Metabolic Research, 16:56-65, Feb 2021. URL: https://doi.org/10.1016/j.coemr.2020.09.002, doi:10.1016/j.coemr.2020.09.002. This article has 29 citations and is from a peer-reviewed journal.
19. (sulon2021targetinggprotein–coupled pages 7-9): Sarah M. Sulon and Jeffrey L. Benovic. Targeting g protein–coupled receptor kinases to g protein–coupled receptors. Current Opinion in Endocrine and Metabolic Research, 16:56-65, Feb 2021. URL: https://doi.org/10.1016/j.coemr.2020.09.002, doi:10.1016/j.coemr.2020.09.002. This article has 29 citations and is from a peer-reviewed journal.
20. (gurevich2012gproteincoupledreceptor pages 25-27): Eugenia V. Gurevich, John J.G. Tesmer, Arcady Mushegian, and Vsevolod V. Gurevich. G protein-coupled receptor kinases: more than just kinases and not only for gpcrs. Pharmacology & Therapeutics, 133:40-69, Jan 2012. URL: https://doi.org/10.1016/j.pharmthera.2011.08.001, doi:10.1016/j.pharmthera.2011.08.001. This article has 544 citations.
21. (gurevich2012gproteincoupledreceptor pages 6-8): Eugenia V. Gurevich, John J.G. Tesmer, Arcady Mushegian, and Vsevolod V. Gurevich. G protein-coupled receptor kinases: more than just kinases and not only for gpcrs. Pharmacology & Therapeutics, 133:40-69, Jan 2012. URL: https://doi.org/10.1016/j.pharmthera.2011.08.001, doi:10.1016/j.pharmthera.2011.08.001. This article has 544 citations.